Buprenorphine hydrochloride with naloxone hydrochloride
Brand: Suboxone®
PBAC's latest decision on Buprenorphine hydrochloride with naloxone hydrochloride: Recommended with restriction (2005). Considered for treatment of opiate dependence, within a framework of medical, social and psychological treatment.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2005
Submissions
1
2005 → 2005
Eligible population
opiate-dependent patients
Therapy area
Pain
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Other
Pivotal trial size
323 patients
Key trials
Fudala PJ Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. 2003;349(10):949-58.
Comparator
buprenorphine alone
Economic model
Cost-minimisation
Eligible patients/year
10,000
ICER note
Cost-minimisation approach used; no ICER calculated